You are here

Article Text

Article menu

Download PDFPDF

PostScript
Correspondence
Effect of CPAP on the metabolic syndrome: a randomised sham-controlled study
Free
  1. CM Hoyos1,
  2. DR Sullivan2,
  3. PY Liu1,3
  1. 1 Endocrine and Cardiometabolic Research Group, NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS), Woolcock Institute of Medical Research , University of Sydney, Sydney, New South Wales, Australia
  2. 2 Biochemistry Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  3. 3 Division of Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California, USA
  1. Correspondence to Dr Peter Y Liu, Division of Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, 1124 W. Carson Street, Torrance, CA 90502, USA; pliu{at}labiomed.org

https://doi.org/10.1136/thoraxjnl-2012-203074

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A recently published editorial1 concluded that severity of disease, Continuous Positive Airway Pressure (CPAP) compliance and comorbidities might explain discrepancies between a randomised sham-controlled crossover study2 which showed that CPAP reversed metabolic syndrome (metS) and reduced weight, body mass index (BMI) and visceral abdominal fat and our findings from a randomised sham-controlled parallel-group study.3 Whether CPAP might be a novel method to reverse metS in those with Obstructive Sleep Apnea (OSA) is an intriguing possibility, since diagnosing and treating metS is important.1 We omitted to examine the effect of CPAP on metS in our population, a typical OSA cohort with treated long-standing metabolic comorbidites and less than ideal CPAP usage.1 To rectify this, we retrospectively assayed stored blood …

    View Full Text